Navigation Links
Palatin Technologies, Inc. To Report Fiscal Year 2013 First Quarter Results; Teleconference and Webcast to be held on November 14, 2012
Date:11/9/2012

CRANBURY, N.J., Nov. 9, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its first quarter, fiscal year 2013 financial results on Wednesday, November 14, 2012 before the open of the U.S. financial markets.

Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on November 14, 2012, which will include discussion of the results of operations in greater detail and an update on corporate developments.Schedule for the Financial Results Press Release, Conference Call / Webcast

  • Q1 Fiscal Year 2013 Financial Results Press Release
  • 11/14/2012 at 7:30 a.m. ET

     

  • Q1 Fiscal Year 2013 Conference Call-Live
    Domestic Dial-In Number
    International Dial-In Number
    Passcode
  • 11/14/2012 at 11:00 a.m. ET
    1-888-428-9490
    1-719-325-2354

    9649528

     

  • Q1 Fiscal Year 2013 Conference Call-Replay
    Domestic Dial-In Number
    International Dial-In Number
    Passcode
  • 11/14/2012-11/20/2012
    1-888-203-1112
    1-719-457-0820
    9649528

     

  • Webcast Live and Replay Access
  • http://www.palatin.comThe webcast and replay can be accessed by logging on to the "Investor/Media Center-Webcasts"

    section of Palatin's website at http://www.palatin.com. About Palatin Technologies, Inc.
    Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.


    '/>"/>
    SOURCE Palatin Technologies, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1

    Related biology technology :

    1. Palatin Technologies Reports Positive Results for Phase 2B Bremelanotide Female Sexual Dysfunction Trial
    2. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
    3. Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
    4. Palatin Technologies, Inc. To Report Fiscal Year 2012 Fourth Quarter Results; Teleconference and Webcast to be held on September 11, 2012
    5. Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
    6. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
    7. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
    8. Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
    9. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
    10. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
    11. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/3/2015)... Santa Clara, California (PRWEB) March 03, 2015 ... and development service company, has launched a new Life ... research reagents for preclinical research. , The first ... monoclonal antibody isotype controls, and soon to be released ... The company will continue to expand their life science ...
    (Date:3/3/2015)... ROCKVILLE, Md. , March 3, 2015  RegeneRx ... an editorial in the scientific journal, Expert Opinion ... and his colleague, Dr. Zhenggang Zhang , at ... reported that Thymosin beta 4 (TB4) has ... (PNS) remodeling 24 hours or more post-injury, leading to ...
    (Date:3/3/2015)... March 03, 2015 Becht Engineering ... that it has acquired The CECON Group, Inc., ... transaction were not announced. , Becht Engineering ... energy sector including oil and gas production, refining, ... and nuclear power sectors. The company has twelve ...
    (Date:3/3/2015)... , Mar. 03, 2015 Research and Markets ... addition of Jain PharmaBiotech,s new report "Gene ... their offering. , Gene therapy ... nonviral vectors and cell therapy with genetically modified ... drug delivery and various routes of administration as ...
    Breaking Biology Technology:Crown Bioscience Launches Life Science Product Catalog 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 3Gene Therapy Market Report 2014-2024 - Technologies, Markets and Companies 2Gene Therapy Market Report 2014-2024 - Technologies, Markets and Companies 3
    ... - YM BioSciences Inc.,(AMEX: YMI , TSX: ... and commercializes differentiated products for patients worldwide,today announced ... its,anti-cancer drugs, nimotuzumab and tesmilifene, will be presented ... Meeting held from,April 12-16, 2008 in San Diego, ...
    ... 11 Specto Design, (http://www.spectodesign.com ), a leading ... website for a world renowned biomedical research,institute. (http://www.liai.org ... how to open up the content to the user ... conveying La Jolla Institute for Allergy & Immunology,s dedication ...
    ... 2008 RiverVest Venture Partners,announced today that it ... Fund II, L.P., with total committed capital of ... was licensed,as a Small Business Investment Company, had ... of leverage from the Small Business Administration., ...
    Cached Biology Technology:YM BIOSCIENCES ANNOUNCES PRESENTATIONS FOR TWO OF ITS ANTI-CANCER DRUGS AT AACR ANNUAL MEETING 2YM BIOSCIENCES ANNOUNCES PRESENTATIONS FOR TWO OF ITS ANTI-CANCER DRUGS AT AACR ANNUAL MEETING 3La Jolla Institute for Allergy & Immunology Wows With New Website 2RiverVest Venture Partners(R), a St. Louis-Based Venture Capital Firm Focusing on Life Sciences, Closes on Fund II, Names John P. McKearn, Ph.D., Venture Partner 2RiverVest Venture Partners(R), a St. Louis-Based Venture Capital Firm Focusing on Life Sciences, Closes on Fund II, Names John P. McKearn, Ph.D., Venture Partner 3
    (Date:3/2/2015)... Lithuania , March 2, 2015   Neurotechnology ... technologies, today introduced the SentiGaze Software Development Kit ... to create applications that use off-the-shelf webcams to track ... user gazes at a monitor. Heatmaps can be used ... the effectiveness of online advertising. The SDK can also ...
    (Date:2/24/2015)... NEW YORK , Feb. 24, 2015 This report ... Thousands by the following Segments: Face Biometrics, and Voice Biometrics. The ... , Japan , Europe ... & Africa , and Latin ... period 2013 through 2020. Also, a seven-year historic analysis is provided ...
    (Date:2/19/2015)... , Feb .19, 2015 Research and Markets ... addition of the "Military Electro-Optical / Infrared ... Technology, by Platform - Forecast to 2020" ... military electro-optical/infrared systems market is expected to reach ... of 7.71%. This report segments the ...
    Breaking Biology News(10 mins):Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 2Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 3World Face and Voice Biometrics Industry 2World Face and Voice Biometrics Industry 3World Face and Voice Biometrics Industry 4World Face and Voice Biometrics Industry 5World Face and Voice Biometrics Industry 6World Face and Voice Biometrics Industry 7World Face and Voice Biometrics Industry 8World Face and Voice Biometrics Industry 9World Face and Voice Biometrics Industry 10World Face and Voice Biometrics Industry 11World Face and Voice Biometrics Industry 12World Face and Voice Biometrics Industry 13World Face and Voice Biometrics Industry 14World Face and Voice Biometrics Industry 15World Face and Voice Biometrics Industry 16Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3
    ... Using a high-resolution single-molecule study technique, University of ... between two branches of an important family of ... research scientist Gisela Cymes published their work in ... are proteins embedded in the membranes of nerve ...
    ... pregnancy increases the chance of stillbirth, according to new research ... eating a typical American diet, which is high in fat, ... temporary organ that nourishes the unborn fetus. Prior to this ... unclear. The findings are published in the June edition of ...
    ... The Woods Hole Oceanographic Institution (WHOI) will lead the ... of radioactive substances in the Pacific Ocean off the ... Gordon and Betty Moore Foundation. "This ... this release of radiation to the ocean, and in ...
    Cached Biology News:Small change makes a big difference for ion channels 2Small change makes a big difference for ion channels 3Study reveals how high-fat diet during pregnancy increases risk of stillbirth 2Woods Hole Oceanographic Institution leads expedition to measure radioactive contaminants in Pacific 2Woods Hole Oceanographic Institution leads expedition to measure radioactive contaminants in Pacific 3Woods Hole Oceanographic Institution leads expedition to measure radioactive contaminants in Pacific 4Woods Hole Oceanographic Institution leads expedition to measure radioactive contaminants in Pacific 5
    Recognizes rat Taste Receptor 2 (TR2). The immunogen shows no significant sequence homology with TR1, gustducin or other pheromone receptors....
    ... Yersinia pestis This antibody is ... Immunogen: Purified F1 ... vaccine strain EV76. Specificity: ... capsular antigen. There is no cross-reactivity ...
    Human Ig Lambda-chain, clone ICO-16, Monoclonal Antibody...
    Neutrophil cytosol factor 2 (NCF-2) (Neutrophil NADPH oxidase factor 2) (67 kDa neutrophil oxidase factor) (p67-phox) (NOXA2). [Source:Uniprot/SWISSPROT;Acc:P19878] Antigen: Recombinant Protein E...
    Biology Products: